Michael Staehler Dan George Alain Ravaud Kudos to Jean-Francois Martini and Keith Ching from Pfizer for providing the SCIENCE and their effort in getting this published. I hope it serves as a model for study of the IO adjuvant phase 3 trials in RCC.

Molecular characterization of #kidneycancer allows for prediction of risk of recurrence. MERTK and TDO2 should be investigated in future trials. Amazing data from Robert Motzer MD Dan George Alain Ravaud and others. rdcu.be/cXe1y

DoM's Chung-Han Lee 李宗翰, MD/PhD recently published results from a phase 2 trial in Journal of Clinical Oncology that showed cabozantinib/nivolumab was effective in the treatment of papillary, unclassified, or translocation-associated renal cell carcinoma. Read the study ⬇️ #Cancer
📖: ow.ly/oX7050JRFe6

Happy to share the results of our randomized phase II of intense ADT prior to prostatectomy for high-risk prostate cancer, including PSMA/PET correlation with path outcomes! Rana McKay silke gillessen Andrey Soares Rafael Coelho Sumanta Pal Guillermo de Velasco Dana Rathkopf

WATCH: A clinical scenario of renal cell carcinoma treated with surgery and adjuvant pembrolizumab is reviewed by a panel of experts. Marie Carlo Robert Motzer MD Chung-Han Lee 李宗翰, MD/PhD Memorial Sloan Kettering Cancer Center #kcsm ow.ly/j70T50JygnP

1/ CheckMate-9ER extended f/u (media f/u=32.9mo) results out in The Lancet Oncology: preplanned final OS analysis, updated PFS, OR & safety of Cabo/Nivo vs. Sun in 1L RCC. Also includes prespecified & post-hoc subgroup analyses.
sciencedirect.com/science/articl…

OncoAlert Dana-Farber Lank Center for Genitourinary Oncology

My TOP3 abstracts in #RCC at #ASCO22 :
EVEREST: Almost hit the bar for adjuvant everolimus Charles Ryan
CALYPSO: Biology is capricious Tom Powles
CM-214: There is no better QoL than responding no matter to what treatment Robert Motzer MD
GrupoCentroGU

Thrilled to get the chance to do a discussion of ASCO posters with patient advocates

RNAseq cluster data from JAVELIN renal 101. Largely mirrors IMmotion data. Time to use this prospectively to select patients. #OPTICtrial . ⁦Toni Choueiri, MD⁩ ⁦Robert Motzer MD⁩

Introducing Chris Labaki Renee Maria Saliby from Dana-Farber Lank Center for Genitourinary Oncology to Robert Motzer MD for all #RCC topics !
#ASCO22 ASCO OncoAlert

ROUNDTABLE:
Recent Advances in Tivozanib + Nivolumab Strategies in #RenalCellCarcinoma
PANELISTS Robert Motzer MD Toni Choueiri, MD Laurence Albiges & Dr. Figlin

📕PDF article bit.ly/3NToWWh
📺Video kidney-cancer-journal.com/KCJ20n2-rt.php

More info available AVEO Oncology Booth# 20147 #ASCO22 Meeting

#ASCO22 Important data presented by Robert Motzer MD of HRQoL and its association with clinical outcomes in patients with advanced #kidneycancer from the Checkmate-214 trial
ASCO OncoAlert

Proof of concept of dual inhibition of glucose and glutamine carbon metabolism in patients with late line RCC. Would love to see whether molecular/metabolic selection of patients would enhance efficacy. Critical to develop new pathways in RCC aacrjournals.org/clincancerres/… Clinical Cancer Research

Negative study for MEDI0680 + Durvalumab vs. Nivolumab in RCC, but really interesting to see decrease in ctDNA at 4 weeks was associated with improved PFS. Look forward to seeing whether this is replicated in other trials. Martin Voss doi.org/10.1158/1078-0…

Health-related quality-of-life outcomes in patients w/advanced renal cell carcinoma treated with lenvatinib + pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study - ⁦The Lancet Oncology⁩ ⁦Robert Motzer MD⁩ ⁦David Cella⁩ sciencedirect.com/science/articl…

Tom Powles Uromigos Special thanks to you Tom for having the Giants of CancerCare Bernard Escudier Toni Choueiri, MD Robert Motzer MD incredible line up for your intro! Honored and Thankful to Kidney Cancer for this award GustaveRoussy GETUG

Experts review a clinical scenario of intermediate- and poor-risk renal cell carcinoma that is managed with ipilimumab-nivolumab and nivolumab maintenance. Robert Motzer MD Marie Carlo Chung-Han Lee 李宗翰, MD/PhD Memorial Sloan Kettering Cancer Center #kcsm ow.ly/QIE350IIOB7

Now published in Eur Urol Focus by UrologyMSK Angela Yoo
Phillip Rappold Robert Motzer MD ari hakimi et al:
Genomic and metabolic hallmarks of SDH- and FH-deficient renal cell carcinomas
eu-focus.europeanurology.com/article/S2405-…

So proud of our fellow Kelly Fitzgerald 's review article in JNCCN. Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options jnccn.org/view/journals/… #RCC Robert Motzer MD Jonathan Rosenberg MD